Gene Name	Entrez ID	Drug Name	Chembl ID	Interaction Types	Sources	publications

Gene Name	Variant	Alleles	Chemical	Phenotype Category	Significance	Notes	Sentence	Publications	Annotation ID
PAX4	rs10229583	AA + AG	repaglinide	efficacy	no	No significant differences in any clinical parameters (e.g. body mass index, fasting glucose, 2-hour glucose) or attainment rates of target fasting glucose, 2-hour glucose or glycated hemoglobin were seen after 48 weeks of treatment between the genotypes. Study Size and Frequency below: repaglinide cohort/rosiglitazone cohort.	Genotypes AA + AG are not associated with response to repaglinide or rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	24752311	1296666710
PAX4	rs6467136	AA + AG	rosiglitazone	efficacy	yes	Subset of patients with defective beta-cell function. Those with the AA or AG genotype had a greater decrease in body mass index (BMI) after 48 weeks of treatment, as compared to GG homozygotes. Those with the AA and AG genotypes also showed a greater improvement of HOMA-IR as compared to GG homozygotes. Lastly, those with the AA and AG genotypes were significantly more likely to attain the standard fasting plasma glucose and 2-hour glucose levels as compared to GG homozygotes at all assessment points between 0 and 48 weeks of treatment. Note that these effects were not seen in the subgroup with normal beta-cell function.	Genotypes AA + AG are associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	24752311	1296666726
PAX4	rs6467136	AA + AG	rosiglitazone	efficacy	yes	Those with the AA or AG genotype had a greater decrease in 2-hour glucose levels after 48 weeks of treatment and a greater decrease in body mass index (BMI) after 48 weeks of treatment, as compared to GG homozygotes. Those with the AA and AG genotypes were also significantly more likely to attain the standard 2-hour glucose level as compared to GG homozygotes at all assessment points between 0 and 48 weeks of treatment.	Genotypes AA + AG are associated with increased response to rosiglitazone in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	24752311	1296666686
PAX4	rs6467136	AA + AG	repaglinide	efficacy	no	No significant differences in any clinical parameters (e.g. body mass index, fasting glucose, 2-hour glucose) or attainment rates of target fasting glucose, 2-hour glucose or glycated hemoglobin were seen after 48 weeks of treatment between the genotypes.	Genotypes AA + AG are not associated with response to repaglinide in people with Diabetes Mellitus, Type 2 as compared to genotype GG.	24752311	1296666702